Evidence map›Paper›PMID 42549470›Full record

ArticleFujita medical journal2026

Severe bradycardia after amivantamab administration in a patient with epidermal growth factor receptor-positive non-small cell lung cancer: A case report.

Shoko Kamenosono, Aki Ikeda, Hideaki Takahashi, Toshikazu Watanabe, Tetsunari Hase, Nanami Kiryu, Shin Hasegawa, Yoshiko Shigeyasu, Tomohide Souma, Tomoya Horiguchi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fujita medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shoko KamenosonoDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Aki IkedaDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hideaki TakahashiDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Toshikazu WatanabeDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Tetsunari HaseDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Nanami KiryuDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Shin HasegawaDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yoshiko ShigeyasuDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Tomohide SoumaDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Tomoya HoriguchiDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yasuhiro GotoDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Naozumi HashimotoDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Kazuyoshi ImaizumiDepartment of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amivantamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, has shown clinical efficacy in patients with

Indexed as

AmivantamabBradycardiaInfusion-related reactionsNon-small cell lung cancer

Identifiers

PMID42549470
PMCPMC13433100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.